David Su is a Founding Managing Partner of Matrix China. David has been investing in China for the last two decades and some of his investments include Baidu (NASDAQ: BIDU/HK: 9888), Didi Chuxing (NYSE: DIDI), XPeng (NYSE: XPEV/HK: 9868), Bona Film (NASDAQ: BONA), Focus Media (CH: 002027), Kanghui Medical (acquired by Medtronic in 2012), Kingfriend Biochemical (CH: 603707), China Youzan (HK: 8083), AAC Technologies (HK: 2018), Ele.me (acquired by Alibaba in 2018), ClouDr Group, Guomai Culture Media (CH: 301052), Chicecream, Kujiale, etc.

Before founding Matrix China, David was a Founding General Partner of TDF Capital and KPCB China. Prior to joining the venture capital industry, David worked at Lotus Development, IBM Software Group for seven years and was last responsible for Lotus software and services business in the Greater China Region.

David Su has been awarded the Annual Most Influential VC Investor by China Renaissance in 2019 and the Top100 Best Investors by Forbes in 2020. He has also been recognized as Top10 China Best Healthcare Investors by 36Kr in 2020. In 2021, David has been named the Top50 Best Venture Investors by China Venture and Annual TOP50 Investor by Yicai Media.